Analyst Price Targets — CANF
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 2, 2026 10:41 am | — | H.C. Wainwright | $8.00 | $4.63 | StreetInsider | Can-Fite BioPharma (CANF) PT Raised to $8 at H.C. WainwrightMember Login |
| May 12, 2026 10:14 am | Swayampakula Ramakanth | H.C. Wainwright | $5.00 | $3.36 | TheFly | Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright |
| April 15, 2025 11:02 am | James Molloy | Industrial Alliance Securities | $90.00 | $31.40 | TheFly | Can-Fite price target lowered to $4.50 from $12 at Alliance Global Partners |
| July 17, 2024 7:06 am | Jason Kolbert | EF Hutton | $200.00 | $73.20 | TheFly | Can-Fite BioPharma initiated with a Buy at EF Hutton |
Latest News for CANF
The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced new preclinical findings…
Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today provided…
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced…
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months
Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Australian Patent Office has allowed Patent Application No.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CANF.
U.S. House Trading
No House trades found for CANF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.